This is a promotional website intended for UK Healthcare Professionals (HCPs) only. Please note that some content is only relevant for HCPs practising in Great Britain.

Japanese encephalitis vaccine


Japanese encephalitis vaccine
(inactivated, absorbed).
IXIARO® is the only licensed and recommended Japanese encephalitis (JE) vaccine in the UK1. Help protect your travellers against Japanese encephalitis.


Key facts

  • Licensed for adults and children 2 months of age and older1,2
  • Results in rapid protection from JE after the second dose (>97% seroconversion a week after the second dose), providing a protective response that lasts for at least 12 months2,3
  • Is generally well-tolerated in adults and children4
  • The most common adverse reactions in clinical trials included pain and tenderness at the injection site (33%), headache (20%), myalgia (13%) and fatigue (12.9%)1,2
  • Available as pre-filled syringes and administered as a two dose schedule2
    • Rapid schedule (for 18 – 65 years of age only): day 0 and day 7
    • Conventional schedule: day 0 and day 28
  • A booster dose should be given to adults and children 2 months of age and older within the second year (i.e. 12 – 24 months), prior to potential re-exposure to the JE virus2
  • A second booster dose should be given to adults 18 years of age and above 10 years after the first booster dose, prior to potential re-exposure to the JE virus2
  • IXIARO® is contraindicated in individuals who have had an anaphylactic or serious systemic reaction to a previous dose of the vaccine or any vaccine component and is not advisable for those who are pregnant or lactating1

How you should administer IXIARO®1,2



View Prescribing InformationFurther information on SMPC Further information on PIL

Place an order


  1. Public Health England. Immunisation against infectious disease. Japanese encephalitis: the green book, chapter 20. June 2018. Available online: (Last accessed March 2023).
  2. Valneva UK Limited – IXIARO® Summary of Product Characteristics, April 2021. Available online: (Last accessed March 2023).
  3. Schuller E, Jilma B, Voicu V, et al. Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51. Six and 12 month results of a nmulticenter follow-up phase 3 study. Vaccine. 2008;26(34):4382-4386.
  4. Tauber E, Kollaritsch H, von Sonnenburg F, et al. Randomized, double-blind, placebo- controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine. J Infect Dis. 2008;198(4):493-499.

Adverse events should be reported.
Reporting forms and information can be found at or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to the Valneva UK Ltd Medical Information department on Tel: 01506 446608 or via email:

2024 - Please use a modern browser